298 papers
Cancer biology explores the complex ways cells grow out of control, investigating the genetic mutations and environmental factors that drive tumor formation. This field seeks to understand how healthy cells transform into malignant ones and how these rogue cells spread throughout the body. By decoding these fundamental mechanisms, researchers aim to develop more effective treatments that target the disease at its source while sparing healthy tissue.
At Gist.Science, we process every new preprint published in this category directly from bioRxiv to ensure you stay ahead of the curve. Our team provides both accessible plain-language overviews and detailed technical summaries for each study, bridging the gap between raw research data and practical understanding. Whether you are a specialist or a curious reader, our goal is to make these critical findings clear and actionable.
Below are the latest papers in cancer biology, offering fresh insights into the ongoing fight against this disease.
This study demonstrates that inhibiting AKT with capivasertib triggers ESCRT-dependent lysosomal degradation of YAP, thereby overcoming adaptive resistance to RAS pathway inhibition and significantly improving therapeutic outcomes in pancreatobiliary cancers.
This study presents a comprehensive temporal proteome and phosphoproteome dataset of Y1 adrenocortical cells under FGF2 stimulation and SOS inhibition, revealing thousands of differentially abundant sites to elucidate the complex signaling mechanisms governing the life-death switch and stress responses in this KRAS-driven tumor model.
This study demonstrates that estradiol induces cell death in ER+ breast cancer cells via TOP2-mediated DNA double-strand breaks, thereby sensitizing these cells to TOP2 poisons like doxorubicin while rendering them resistant to the catalytic TOP2 inhibitor T638.
This paper presents a mathematical model of oncolytic viral therapy applied to both primary and metastatic tumors, revealing that immune modulation intended to enhance treatment may paradoxically promote distant metastasis and that vascular disrupting agents could have opposing effects depending on tumor size.
This study reports the development of compound #63, a first-in-class picomolar LZK inhibitor that suppresses tumor growth in head and neck and esophageal cancers and significantly enhances the efficacy of EGFR- and PI3K-targeted therapies through synergistic combination strategies.
This study demonstrates that [18F]Itareparib is a brain-penetrant, metabolically stable, and PARP1-selective radioligand capable of specific tumor uptake and reversible binding in glioma models, supporting its potential for quantitative PET imaging and target occupancy studies in neurooncology.
This study identifies a stromal chondroitin-4-sulfate (C4S)-rich extracellular matrix state as a non-genetic determinant of platinum resistance in ovarian cancer, demonstrating that high C4S levels correlate with carboplatin resistance but predict sensitivity to the GAG-targeting agent Triplatin, thereby offering a novel glycomics-based biomarker for guiding treatment strategies.
This study demonstrates that protruding vascular geometries create mechanical hotspots where a viscoelastic polymer-like network captures circulating tumor cells, revealing local vessel topography as a critical determinant of metastatic homing and identifying DSG2 and ITGB3 as potential therapeutic targets.
The paper introduces Rapid Micronucleus-Sequencing (RaMN-Seq), a fast and cost-effective method for purifying and sequencing micronuclei that enables the rapid characterization of chromosomal instability patterns in both induced and spontaneous contexts across diverse cell types and tumor samples.
This study reveals that metabolic reprogramming in breast cancer drives the remodeling of cell-surface glycoRNA via c-Myc-mediated DTWD2 repression, which suppresses innate and adaptive antitumor immunity and correlates with poor prognosis, while restoring glycoRNA enhances the efficacy of PD-1 blockade.